BCRX BioCryst Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

BCRX [NASD]

BioCryst Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	0.10%	Shs Outstand	161.57M	Perf Week	-9.23%
Market Cap	605.59M	Forward P/E	-	EPS next Y	-0.83	Insider Trans	48.06%	Shs Float	161.13M	Perf Month	-8.66%
Income	-116.40M	PEG	-	EPS next Q	-0.25	Inst Own	76.90%	Short Float	21.50%	Perf Quarter	-24.64%
Sales	49.20M	P/S	12.31	EPS this Y	4.00%	Inst Trans	9.78%	Short Ratio	5.25	Perf Half Y	90.58%
Book/sh	0.47	P/B	7.74	EPS next Y	10.80%	ROA	-75.50%	Target Price	-	Perf Year	19.54%
Cash/sh	1.14	P/C	3.20	EPS next 5Y	19.90%	ROE	-603.60%	52W Range	1.38 - 6.29	Perf YTD	5.51%
Dividend	-	P/FCF	-	EPS past 5Y	-6.80%	ROI	-84.10%	52W High	-43.45%	Beta	2.62
Dividend %	-	Quick Ratio	1.90	Sales past 5Y	29.10%	Gross Margin	94.60%	52W Low	157.61%	ATR	0.24
Employees	140	Current Ratio	2.00	Sales Q/Q	107.10%	Oper. Margin	-	RSI (14)	40.89	Volatility	6.69% 6.44%
Optionable	Yes	Debt/Eq	1.05	EPS Q/Q	29.90%	Profit Margin	-	Rel Volume	0.60	Prev Close	3.64
Shortable	Yes	LT Debt/Eq	0.41	Earnings	Aug 06 BMO	Payout	-	Avg Volume	6.60M	Price	3.56
Recom	2.10	SMA20	-6.63%	SMA50	-13.78%	SMA200	-2.52%	Volume	1,816,718	Change	-2.34%

Jun-17-20

Initiated

BTIG Research

Neutral

May-05-20

Upgrade

Barclays

Equal Weight → Overweight

Nov-15-19

Upgrade

BofA/Merrill

Neutral → Buy

$5 → $4

May-24-19

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$16 → $4.50

Nov-16-18

Resumed

Piper Jaffray

Overweight

$15

Aug-08-18

Resumed

JP Morgan

Overweight

Jul-17-18

Upgrade

BofA/Merrill

Underperform → Neutral

Jun-22-18

Initiated

Seaport Global Securities

Neutral

Jan-02-18

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

Dec-20-17

Initiated

Barclays

Equal Weight

Sep-15-17

Initiated

RBC Capital Mkts

Sector Perform

Sep-06-17

Upgrade

JP Morgan

Neutral → Overweight

Sep-06-17

Upgrade

Jefferies

Hold → Buy

Feb-16-17

Initiated

Ladenburg Thalmann

Buy

$11

Aug-12-16

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-04-16

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Feb-09-16

Reiterated

FBR Capital

Outperform

$18 → $6

Feb-09-16

Downgrade

Needham

Buy → Hold

Feb-09-16

Downgrade

JP Morgan

Overweight → Neutral

Feb-09-16

Downgrade

Jefferies

Buy → Hold

Sep-22-20 07:25AM	Does BioCryst Pharmaceuticals (NASDAQ:BCRX) Have A Healthy Balance Sheet? Simply Wall St.
Sep-08-20 07:00AM	BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Sep-03-20 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.67%
07:00AM	U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile GlobeNewswire
Aug-31-20 09:29AM	NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir GlobeNewswire
07:00AM	FDA Grants Orphan Drug Designation for BCX9930 in PNH GlobeNewswire
Aug-17-20 11:41AM	BioCryst Pharmaceuticals' (NASDAQ:BCRX) Shareholders Are Down 62% On Their Shares Simply Wall St. +5.23%
Aug-13-20 01:48PM	Here's Why BioCryst Pharmaceuticals Jumped Higher Today Motley Fool +15.87%
Aug-11-20 08:54AM	Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't? Zacks
Aug-06-20 09:55AM	BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM	BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones GlobeNewswire
Aug-04-20 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-03-20 11:19AM	Is BioCryst Pharmaceuticals Stock a Buy? Motley Fool +8.11%
07:00AM	FDA Grants Fast Track Designation for BCX9930 in PNH GlobeNewswire
Jul-23-20 07:00AM	BioCryst to Report Second Quarter 2020 Financial Results on August 6 GlobeNewswire
Jul-18-20 07:16PM	Did Hedge Funds Make The Right Call On BioCryst Pharmaceuticals, Inc. (BCRX) ? Insider Monkey
Jul-15-20 11:35AM	Better Buy: Moderna vs. BioCryst Pharmaceuticals Motley Fool
Jul-07-20 02:43PM	BioCryst Pharmaceuticals Jumped Higher Today; Here's Why Investors May Be Wrong Motley Fool +9.29%
11:57AM	What You Need To Know About BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Investor Composition Simply Wall St.
11:30AM	Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? Zacks
Jul-02-20 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-18-20 08:53AM	Implied Volatility Surging for BioCryst (BCRX) Stock Options Zacks
Jun-15-20 07:43AM	Hedge Funds Have Never Been This Bullish On BioCryst Pharmaceuticals, Inc. (BCRX) Insider Monkey
Jun-10-20 02:00PM	Galidesivir Stops Zika Viral Replication in Primate Model GlobeNewswire +6.03%
Jun-09-20 04:15PM	BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States GlobeNewswire
Jun-08-20 03:40PM	Here's Why BioCryst Pharmaceuticals Jumped 15% in May Motley Fool +5.52%
Jun-06-20 03:01AM	Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication GlobeNewswire
03:00AM	Long-term (48-week) Data Show Treatment with Berotralstat Provides Robust and Durable Reductions in HAE Attacks and Improvements in Quality of Life Scores GlobeNewswire
Jun-02-20 07:15AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-01-20 04:01PM	BioCryst Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
May-28-20 04:15PM	BioCryst to Present at Jefferies Virtual Healthcare Conference GlobeNewswire -10.72%
May-27-20 11:35PM	BioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
06:21PM	BioCryst Plans to Raise $100 Million Motley Fool
04:01PM	BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
May-26-20 07:00AM	BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress GlobeNewswire
12:36AM	Edited Transcript of BCRX earnings conference call or presentation 6-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-19-20 03:18PM	Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example' Yahoo Finance Video
May-18-20 02:47PM	Moderna COVID-19 vaccine data is baby-step in right direction: Expert Yahoo Finance Video -6.81%
09:30AM	Moving Average Crossover Alert: BioCryst Pharmaceuticals Zacks
09:21AM	Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock? Zacks
May-15-20 07:53AM	BioCryst's Shares March Higher, Can It Continue? Zacks
07:00AM	BioCryst Celebrates HAE Patients with HAE Global Walk GlobeNewswire
May-13-20 11:30AM	Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year? Zacks -9.43%
May-11-20 02:45PM	Here's Why Shares of BioCryst Pharmaceuticals Jumped Higher Today Motley Fool +17.87%
May-07-20 01:07PM	Industry Analysts Just Made A Meaningful Upgrade To Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Revenue Forecasts Simply Wall St.
07:00AM	BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
May-06-20 07:31PM	Biocryst Pharmaceuticals Inc (BCRX) Q1 2020 Earnings Call Transcript Motley Fool
08:55AM	BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:42AM	Recap: BioCryst Pharmaceuticals Q1 Earnings Benzinga
07:00AM	BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones GlobeNewswire
May-05-20 07:00AM	New Composition of Matter Patent Allowance Extends Protection for Berotralstat in U.S. Market by Four Years to 2039 GlobeNewswire
May-04-20 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +11.02%
Apr-29-20 01:17PM	BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards? Zacks +10.78%
01:06PM	BioCryst Pharma Tests Drug Similar to Gilead's Remdesivir TheStreet.com
12:34PM	Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-27-20 05:50PM	BioCryst Pharmaceuticals (BCRX) Stock Sinks As Market Gains: What You Should Know Zacks
11:30AM	Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? Zacks
Apr-26-20 07:51AM	3 Biotech Stocks Under $4 With Big Upside Potential TipRanks
Apr-22-20 07:00AM	BioCryst to Report First Quarter 2020 Financial Results on May 6 GlobeNewswire +7.48%
06:16AM	How Does BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Affect Your Portfolio Volatility? Simply Wall St.
Apr-21-20 12:19PM	RedHill's Oncology Candidate to be Tested for Coronavirus Zacks -7.49%
Apr-20-20 09:06AM	Top Ranked Momentum Stocks to Buy for April 20th Zacks
Apr-15-20 09:36AM	Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock? Zacks
Apr-14-20 06:29PM	BioCryst Latest to Enter Covid-19 Battle GuruFocus.com +17.45%
02:32PM	Birmingham work will support new clinical trial for COVID-19 treatment American City Business Journals
Apr-13-20 12:27PM	BioCryst Begins Study on Galidesivir for Coronavirus Infection Zacks +13.53%
09:54AM	Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics Benzinga
Apr-10-20 02:06PM	RTP drugmaker will test Ebola treatment on COVID-19 patients American City Business Journals
Apr-09-20 05:52PM	BioCryst stock rallies on start of coronavirus drug study MarketWatch
04:45PM	BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19 GlobeNewswire
Apr-08-20 07:00AM	BioCryst to Present at 19th Annual Needham Healthcare Conference GlobeNewswire
Apr-03-20 06:04PM	Edited Transcript of BCRX earnings conference call or presentation 5-Mar-20 1:30pm GMT Thomson Reuters StreetEvents
07:07AM	BioCryst Sees Hammer Chart Pattern: Time to Buy? Zacks
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-02-20 12:28PM	The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore Zacks +5.01%
07:00AM	BioCryst Appoints Anthony Doyle Chief Financial Officer GlobeNewswire
Apr-01-20 08:18AM	After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys Zacks -5.25%
Mar-30-20 07:00AM	European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat (BCX7353) to Prevent HAE Attacks GlobeNewswire
Mar-17-20 06:41AM	Here's Why BioCryst Pharmaceuticals (NASDAQ:BCRX) Can Manage Its Debt Despite Losing Money Simply Wall St.
Mar-16-20 07:10AM	BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2 GlobeNewswire -20.81%
Mar-13-20 02:30PM	7 Great Stocks for a Small Budget Zacks +9.41%
07:12AM	Cover Story: Triangle life sciences gasping for capital, leaders American City Business Journals
Mar-10-20 12:00PM	BioCryst (BCRX) Upgraded to Strong Buy: Here's Why Zacks -10.79%
09:53AM	Implied Volatility Surging for BioCryst (BCRX) Stock Options Zacks
Mar-09-20 08:03AM	The Dow, and Crude-Oil Prices, Are Plummeting. Some Biotechs Are in the Green. Barrons.com -23.36%
07:41AM	Top Ranked Momentum Stocks to Buy for March 9th Zacks
Mar-05-20 08:25AM	BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates Zacks +9.12%
07:05AM	BioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key Milestones GlobeNewswire
07:00AM	BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930 GlobeNewswire
Mar-03-20 07:00AM	BioCryst to Present at Barclays Global Healthcare Conference GlobeNewswire
Mar-02-20 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire +8.67%
Feb-28-20 09:30AM	BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher Zacks +9.29%
Feb-27-20 12:30PM	Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know Zacks +8.50%
07:00AM	BioCryst to Present New Data at American Academy of Allergy, Asthma & Immunology Annual Meeting GlobeNewswire
Feb-25-20 03:25PM	18 Medical Stocks To Watch Amid The Coronavirus Outbreak Benzinga -5.82%
07:00AM	BioCryst Appoints Alan G. Levin to Board of Directors GlobeNewswire
Feb-20-20 07:00AM	BioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5 GlobeNewswire
Feb-18-20 07:00AM	FDA Accepts BioCrysts NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks GlobeNewswire
Feb-10-20 06:25AM	How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Feb-06-20 07:00AM	BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Doyle Anthony	Chief Financial Officer	Aug 11	Buy	4.08	54,000	220,320	54,000	Aug 12 04:31 PM
Stonehouse Jon P	President & CEO	Nov 18	Buy	1.45	50,000	72,500	778,086	Nov 18 04:17 PM
Sniecinski Megan	Chief Business Officer	Nov 18	Buy	1.45	45,000	65,250	45,000	Nov 18 04:16 PM
LEE KENNETH B JR	Director	Nov 18	Buy	1.45	5,000	7,250	15,252	Nov 18 04:14 PM
INGRAM ROBERT ALEXANDER	Director	Nov 18	Buy	1.45	20,000	29,000	48,088	Nov 18 04:12 PM
Hutson Nancy J	Director	Nov 18	Buy	1.45	10,000	14,500	53,046	Nov 18 04:10 PM
HEGGIE THERESA	Director	Nov 18	Buy	1.45	5,000	7,250	6,672	Nov 18 04:08 PM
Barnes Alane P	Senior VP, Chief Legal Officer	Nov 18	Buy	1.45	20,000	29,000	102,061	Nov 18 04:05 PM
Babu Yarlagadda S	Senior VP - Drug Discovery	Nov 18	Buy	1.45	25,000	36,250	155,587	Nov 18 04:03 PM
ASELAGE STEVE	Director	Nov 18	Buy	1.45	15,000	21,750	21,672	Nov 18 04:01 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience